annual EBITDA:
-$185.82M-$33.65M(-22.11%)Summary
- As of today (September 17, 2025), KROS annual EBITDA is -$185.82 million, with the most recent change of -$33.65 million (-22.11%) on December 31, 2024.
- During the last 3 years, KROS annual EBITDA has fallen by -$129.47 million (-229.76%).
- KROS annual EBITDA is now -15809.59% below its all-time high of -$1.17 million, reached on December 31, 2018.
Performance
KROS EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly EBITDA:
-$39.45M-$191.83M(-125.89%)Summary
- As of today (September 17, 2025), KROS quarterly EBITDA is -$39.45 million, with the most recent change of -$191.83 million (-125.89%) on June 30, 2025.
- Over the past year, KROS quarterly EBITDA has increased by +$10.69 million (+21.32%).
- KROS quarterly EBITDA is now -125.89% below its all-time high of $152.38 million, reached on March 31, 2025.
Performance
KROS quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM EBITDA:
$25.45M+$10.69M(+72.37%)Summary
- As of today (September 17, 2025), KROS TTM EBITDA is $25.45 million, with the most recent change of +$10.69 million (+72.37%) on June 30, 2025.
- Over the past year, KROS TTM EBITDA has increased by +$196.12 million (+114.91%).
- KROS TTM EBITDA is now at all-time high.
Performance
KROS TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
KROS EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -22.1% | +21.3% | +114.9% |
| 3 y3 years | -229.8% | -46.3% | +133.4% |
| 5 y5 years | -1433.2% | -269.1% | +188.2% |
KROS EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -229.8% | at low | -125.9% | +32.4% | at high | +113.7% |
| 5 y | 5-year | -1433.2% | at low | -125.9% | +32.4% | at high | +113.7% |
| alltime | all time | <-9999.0% | at low | -125.9% | +32.4% | at high | +113.7% |
KROS EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2025 | - | -$39.45M(-125.9%) | $25.45M(+72.4%) |
| Mar 2025 | - | $152.38M(-622.9%) | $14.77M(-107.9%) |
| Dec 2024 | -$185.82M(+22.1%) | -$29.14M(-50.1%) | -$185.82M(-0.1%) |
| Sep 2024 | - | -$58.34M(+16.4%) | -$185.94M(+8.9%) |
| Jun 2024 | - | -$50.13M(+4.0%) | -$170.67M(+5.6%) |
| Mar 2024 | - | -$48.21M(+64.8%) | -$161.68M(+6.2%) |
| Dec 2023 | -$152.18M(+46.3%) | -$29.26M(-32.1%) | -$152.18M(-0.2%) |
| Sep 2023 | - | -$43.07M(+4.7%) | -$152.51M(+14.8%) |
| Jun 2023 | - | -$41.15M(+6.3%) | -$132.82M(+12.0%) |
| Mar 2023 | - | -$38.70M(+30.8%) | -$118.63M(+14.1%) |
| Dec 2022 | -$104.00M | -$29.59M(+26.5%) | -$104.00M(+31.2%) |
| Sep 2022 | - | -$23.38M(-13.3%) | -$79.25M(+4.1%) |
| Jun 2022 | - | -$26.96M(+12.0%) | -$76.10M(+17.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2022 | - | -$24.07M(+397.8%) | -$64.67M(+14.8%) |
| Dec 2021 | -$56.35M(+24.5%) | -$4.84M(-76.1%) | -$56.35M(-9.3%) |
| Sep 2021 | - | -$20.23M(+30.3%) | -$62.12M(+15.4%) |
| Jun 2021 | - | -$15.53M(-1.4%) | -$53.85M(+9.9%) |
| Mar 2021 | - | -$15.75M(+48.6%) | -$49.00M(+8.3%) |
| Dec 2020 | -$45.25M(+273.3%) | -$10.60M(-11.4%) | -$45.25M(+21.2%) |
| Sep 2020 | - | -$11.96M(+11.9%) | -$37.34M(+29.3%) |
| Jun 2020 | - | -$10.69M(-10.9%) | -$28.87M(+41.5%) |
| Mar 2020 | - | -$12.00M(+345.9%) | -$20.41M(+84.8%) |
| Dec 2019 | -$12.12M(+937.7%) | -$2.69M(-22.9%) | -$11.04M(+32.2%) |
| Sep 2019 | - | -$3.49M(+57.0%) | -$8.35M(+71.9%) |
| Jun 2019 | - | -$2.22M(-15.5%) | -$4.86M(+84.5%) |
| Mar 2019 | - | -$2.63M | -$2.63M |
| Dec 2018 | -$1.17M | - | - |
FAQ
- What is Keros Therapeutics, Inc. annual EBITDA?
- What is the all time high annual EBITDA for Keros Therapeutics, Inc.?
- What is Keros Therapeutics, Inc. annual EBITDA year-on-year change?
- What is Keros Therapeutics, Inc. quarterly EBITDA?
- What is the all time high quarterly EBITDA for Keros Therapeutics, Inc.?
- What is Keros Therapeutics, Inc. quarterly EBITDA year-on-year change?
- What is Keros Therapeutics, Inc. TTM EBITDA?
- What is the all time high TTM EBITDA for Keros Therapeutics, Inc.?
- What is Keros Therapeutics, Inc. TTM EBITDA year-on-year change?
What is Keros Therapeutics, Inc. annual EBITDA?
The current annual EBITDA of KROS is -$185.82M
What is the all time high annual EBITDA for Keros Therapeutics, Inc.?
Keros Therapeutics, Inc. all-time high annual EBITDA is -$1.17M
What is Keros Therapeutics, Inc. annual EBITDA year-on-year change?
Over the past year, KROS annual EBITDA has changed by -$33.65M (-22.11%)
What is Keros Therapeutics, Inc. quarterly EBITDA?
The current quarterly EBITDA of KROS is -$39.45M
What is the all time high quarterly EBITDA for Keros Therapeutics, Inc.?
Keros Therapeutics, Inc. all-time high quarterly EBITDA is $152.38M
What is Keros Therapeutics, Inc. quarterly EBITDA year-on-year change?
Over the past year, KROS quarterly EBITDA has changed by +$10.69M (+21.32%)
What is Keros Therapeutics, Inc. TTM EBITDA?
The current TTM EBITDA of KROS is $25.45M
What is the all time high TTM EBITDA for Keros Therapeutics, Inc.?
Keros Therapeutics, Inc. all-time high TTM EBITDA is $25.45M
What is Keros Therapeutics, Inc. TTM EBITDA year-on-year change?
Over the past year, KROS TTM EBITDA has changed by +$196.12M (+114.91%)